The billionaire recently bought an obesity drug stock that could soar nearly 20% over the next 12 months, according to Wall ...
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
BioAge (BIOA) stock cratered 70% Friday evening after the company said it was discontinuing a Phase 2 study for its ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes were observed in some patients, sending its shares down ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
According to projections, the global market for obesity drugs could be worth nearly $14 billion by 2032. Zepbound has already ...